We have explored a novel strategy for the targeting of retroviral vectors to particular sites or cell types. This strategy involves a method whereby the infectivity of a retroviral vector is neutralized by treatment of viral particles with a photocleavable, biotinylation reagent. These modified viral vectors possess little to no infectivity for target cells. Exposure of these modified viral vectors to long-wavelength UV light
Introduction
There has been considerable success in the construction of highly infectious amphotropic viral gene transfer vectors. Retroviral vectors possessing either the murine amphotropic envelope glycoprotein or the envelope glycoprotein G of vesicular stomatitis virus (VSV-G), in addition to those vectors based on either adeno-associated virus (AAV) or adenoviruses have been generated which possess transduction efficiencies of 10 8 infectious units/ml and greater. The high transduction efficiencies of these viral vectors make them ideal for use both as research tools and as ex vivo gene transfer reagents for gene therapy procedures. However, the in vivo use of such vectors is restricted because of the broad tropism that these viruses possess. 1, 2 A major challenge, for the use of viruses and viral vectors as biologically useful tools continues to be the ability to target virus-mediated gene transduction to particular areas or cell types of interest. Much of the effort to construct viral vectors with targetable infectivity has involved the genetic modification of viral envelope glycoproteins, most commonly through the fusion of such proteins with binding reagents for particular cell types, such as single-chain antibodies, peptides, and ligands that can bind to cell-surface molecules. [3] [4] [5] Largely, this strategy has proven both unsuccessful and difficult. The genetic manipulation of all retroviral envelope glycoproteins tested thus far has shown that these glycoproteins are highly sensitive to alteration. Fusions of retroviral envelope glycoproteins with a variety of protein species have resulted in the generation of unstable, incorrectly folded, or non-functional proteins. In some cases, targetability to particular cell types was accomplished, but the resulting viral vectors showed markedly reduced transduction efficiencies.
Here, we describe an alternative strategy for the targeting of the infectivity of viral vectors. This strategy uses retroviral vectors, the infectivity of which is inhibited by a chemical modification that can be reversed upon exposure to light of a specific wavelength.
Results
We have explored an alternative strategy for the targeting of viral vectors to particular cell types or sites. This strategy involves a method whereby the infectivity of a viral vector is neutralized by a reversible chemical modification ( Figure 1 ). Such chemically modified viral vectors possess little to no infectivity for potential target cells until an external stimulus is applied. This external stimulus induces a reversal of the neutralizing, chemical modification resulting in a restoration of infectivity to the viral vector. Such an infectivity trigger would possess great potential, as both a research tool and a targetable gene transfer agent, as it would become possible to direct both the time and location of a viral infection in a versatile manner. To test if this strategy can be employed to control the infectivity of retroviral vectors, we used a Moloney murine leukemia virus (MLV)-derived vector. This vector, termed Tel-Ampho, bears the envelope glycoprotein of the 4070A amphotropic murine retrovirus and packages a transducable, bacterial lacZ gene allowing for the easy identification and quantification of infected cells. 6 We tested NHS-PC-LC-Biotin as a modification reagent for the control of infectivity of Tel-Ampho. NHS-PC-LC-Biotin is a biotin derivative containing an Nhydroxysuccinimide ester (NHS) which reacts with primary amino groups by nucleophilic attack. This allows for simple attachment of the biotin moiety to the N-ter- mini and lysine residues of protein molecules. This biotin derivative also contains a photocleavable, 1-(2-nitrophenyl)ethyl moiety, which exhibits efficient cleavage upon exposure to light of wavelengths between 300 and 365 nm. Exposure of proteins, conjugated with NHS-PC-LC-Biotin to 300-365 nm light results in the release of the biotin moieties from the proteins, the conjugation sites (primary amino groups) of which are restored to their original, unmodified form. 7 Treatment of Tel-Ampho with NHS-PC-LC-Biotin at concentrations of 2.5 and 5 mg/ml, greatly reduced the infectivity of this viral vector (Figure 2a) . In some cases, at these concentrations, the infectivity of Tel-Ampho was completely eliminated. The presence of biotinylation reagent on viral vector components was implied by the marked effect of the reagent on the infectivity of TelAmpho. To confirm that the inhibition of infectivity caused by the treatment of NHS-PC-LC-Biotin was due to conjugation of this reagent to virions, and not to the presence of unreacted reagent, Tel-Ampho reacted with NHS-PC-LC-Biotin was combined with excess glycine that efficiently reacts with unreacted NHS-PC-LC-Biotin. Additionally, this post-conjugation treatment with excess glycine was also performed after the removal of unreacted NHS-PC-LC-Biotin from viral vectors by several rounds of ultrafiltration. However, neither of these treatments showed any effect on the infectivity inhibition of Tel-Ampho by treatment with NHS-PC-LC-Biotin. These results, along with the fact that the NHS moiety of NHS-PC-LC-Biotin undergoes rapid hydrolysis in aqueous media 8, 9 suggest that the infectivity inhibition of TelAmpho by NHS-PC-LC-Biotin is caused by conjugation of the biotinylation reagent to viral vectors.
We next tested if the infectivity of Tel-Ampho, which has been inhibited by treatment of NHS-PC-LC-Biotin, could be restored by exposure to 365 nm light. This wavelength of light can cleave NHS-PC-LC-Biotin away from proteins to which it has been conjugated and would cause minimal damage to retroviral particles. Because photocleavage of this reagent results in the original target molecule being restored to its unmodified form, we reasoned that exposure of retroviral vectors treated with NHS-PC-LC-Biotin might regain their infectivity. We treated three different stocks of Tel-Ampho with 2.5 mg/ml NHS-PC-LC-Biotin, which resulted in nearly complete inhibition of their infectivity. These retroviral vectors were then exposed to 365 nm light and at regular intervals, samples of these treated stocks were collected and analyzed for their ability to infect target cells (Figure 2b) . Each of the biotinylated Tel-Ampho stocks showed demonstrative gains in infectivity upon exposure to 365 nm light. Restoration of infectivity occurred within 4-6 min of irradiation. As shown for stock 3, irradiation of biotinylated viral vector resulted in nearly complete restoration of the infectious potential for the viral vector stock. Exposure of viral vectors to 365 nm light for longer than 8 min had a detrimental effect on viral infectivity. This might be caused by the damage of viral components by shorter-wavelength UV light that would also be emitted by the light source used. These data indicate that the inhibition of infectivity caused by the reaction of TelAmpho vectors with NHS-PC-LC-Biotin can be reversed upon exposure of these biotinylated, inactivated retroviral vectors to 365 nm light. These data indicate that these retroviral vectors, when treated with NHS-PC-LC-Biotin, possess light-activatable infectivity. A series of experiments showed that the infectivity of Tel-Ampho was restored to 30-90% of the original infectivity upon photo-irradiation.
We next sought to determine whether activation of retroviral vectors could be performed within the context of virus target cells. To investigate this, Tel-Ampho was treated with 2.5 mg/ml NHS-PC-LC-Biotin as described earlier. Equal amounts of biotinylated Tel-Ampho were then added to cultures of D-17 cells, 10 followed by either irradiation with 365 nm light for 5 min or placement in the dark. As shown in Figure 3 , target cells mixed with biotinylated and nonirradiated viral vectors showed little or no infection. In contrast, those mixtures of viral vectors and cells that had been exposed to 365 nm light showed considerable infection of target cells. No detectable difference in cell viability or growth rate was observed between the irradiated and nonirradiated cultures, indicating that neither the exposure of long-wavelength UV light nor unreacted biotinylation reagent, if present, had any effect on cell growth or viability. These data demonstrate that the infectivity of these viral vectors can be activated in situ. This offers the potential for the use of this strategy to target viral vector infection at a location of interest by using focused light.
To determine which viral components were biotinylated by treatment with NHS-PC-LC-Biotin, we analyzed biotinylated, inactivated Tel-Ampho using Western blotting analysis. Concentrated Tel-Ampho was treated with 2.5 mg/ml NHS-PC-LC-Biotin as above. The resulting Tel-Ampho samples were subject to gel filtration chromatography using Sephacryl S-1000 followed by passage through a 0.45-m filter and subsequent centrifugation (to purify virions from other materials). 11 The resulting viral vectors were either irradiated with 365 nm light or kept in a dark place before the separation of viral components by SDS-PAGE. 12 Biotinylated viral components were identified by using a streptavidin-peroxidase conjugate as a probe after transfer to PVDF membrane ( Figure 4a ). Biotinylated proteins are found at approximately 150, 30, 25 and 15 kDa on the blot (lane B). The molecular masses of these protein species suggest that they are the gag-pol and gag protein products of MLV. 13 This is supported by the fact that these biotinylated viral components comigrate with proteins that are immunoreactive with polyclonal antibody against disrupted murine leukemia virus particles (lane A). In contrast, the TelAmpho that was treated with NHS-PC-LC-Biotin and subsequently subjected to irradiation with 365 nm light shows markedly less binding by the streptavidin-peroxidase conjugate (lane C). In particular, the viral components of approximately 150, 25 and 15 kDa, seen in nonirradiated Tel-Ampho (lane B), are absent in the lane containing an equal amount of irradiated virus (lane C). However, a biotinylated viral component of approximately 30 kDa remains readily detectable, although the signal intensity is reduced. This indicates that removal of NHS-PC-LC-Biotin from this viral component did not occur to completion under the exposure conditions used. From its molecular mass, this protein species is the core (gag) antigen of MLV. The location of this protein in virions at the viral core may render it less susceptible to photon irradiation, compared with matrix (p15) or gagpol (approximately 200 kDa) components, which are membrane-associated and thus should be readily access- ible to light. These data suggest that biotinylation of the core gag antigen is not the cause of infectivity inhibition by treatment with NHS-PC-LC-Biotin. Also notable is the apparent lack of detectable signal for the gene products of env (80 kDa) and pol (80 kDa). This may be caused by the lack of sensitivity in this analysis, since these viral components exist in much smaller amounts than the gag gene products in mature virion particles. 13 Thus, from this analysis, we are unable to determine whether or not the gene products of env and pol are biotinylated by treatment with NHS-PC-LC-Biotin.
Figure 2 (a) Effect of treatment with NHS-PC-LC-Biotin on the infectivity of Tel-Ampho. Serial dilutions of 25 mg/ml NHS-PC-LC-Biotin were made in dimethylformamide (DMF) and were allowed to react with aliquots (200 l) of Tel-Ampho for 150 min before halting the reaction and was followed by viral infectivity assay (as described in Materials and methods). DMF was found to have no effect on virion infectivity at dosages up to 30% (data not shown

Figure 3 Light-activated infection of D-17 cells. Tel-Ampho (50 l), concentrated as described in Materials and methods and subsequently treated with 2.5 mg/ml NHS-PC-LC-Biotin for 150 min, was placed within each of six 35-mm culture dishes containing monolayers of D-17 cells
The effect of biotinylation on the reverse transcriptase (RT) (a pol gene product) activity of Tel-Ampho particles was determined by RT assays. Tel-Ampho was treated with NHS-PC-LC-Biotin and divided into two samples, one irradiated with 365 nm light and the other kept in the dark. RT assays on these samples after disruption of virions (Figure 4b) show that biotinylation of Tel-Ampho with NHS-PC-LC-Biotin resulted in an approximate 50% decrease in RT activity. However, exposure of the biotinylated Tel-Ampho to 365 nm light had no significant effect on the RT activity. These data indicate that the RT activity was reduced by treatment of Tel-Ampho, suggesting biotinylation of virion-associated RT. However, because the reduction of RT activity caused by NHS-PC-LC-Biotin was not restored by irradiation, it is unlikely that modulation of RT activity can account for the infectivity inhibition by biotinylation and its restoration upon light irradiation.
Although the biotinylation of the env gene product was not apparent by Western blotting analysis (Figure 4a Tel-Ampho was inactivated by psoralen treatment as above, and then biotinylated with NHS-PC-LC-Biotin. The resulting psoralen-inactivated, biotinylated TelAmpho was tested for the ability to inhibit the infection of target cells by unaltered Tel-Ampho. The psoraleninactivated, biotinylated Tel-Ampho was demonstrably less effective than psoralen-inactivated, nonbiotinylated Tel-Ampho in blocking the infection of target cells by unaltered Tel-Ampho. When 10 4 target cells were used, psoralen-inactivated, biotinylated Tel-Ampho was approximately 45-fold less effective at inhibiting the infectivity of unaltered Tel-Ampho than their inactivated, nonbiotinylated counterpart. These data imply that biotinylation of Tel-Ampho with NHS-PC-LC-Biotin results in a loss of the function of the envelope glycoprotein. Therefore, it is possible that the infectivity inhibition caused by NHS-PC-LC-Biotin treatment is due to the inability of biotinylated viral vectors to bind to and/or to enter target cells. The possibility of this as a mechanism of infectivity inhibition is supported by the observation that a similar biotinylation reagent, which is charged and highly watersoluble (sulfo-NHS-LC-Biotin; Pierce Chemical), inactivated the infectivity of Tel-Ampho at identical concentrations as NHS-PC-LC-Biotin (data not shown). This water-soluble biotinylation reagent is incapable of pass-
Figure 4 (a) Western blotting analysis of biotinylated, purified Tel-Ampho. Lane A, Western blot of lysed Tel-Ampho, detected with polyclonal antiserum raised against disrupted MLV. The data shown are representative of two experiments. (b) Effect of biotinylation on reverse transcriptase activity of TelAmpho. (c) Analysis of the effect of biotinylation on the function of the env gene product using a viral interference assay. A, Tel-Ampho with psoraleninactivated Tel-Ampho; B, Tel-Ampho with psoralen-inactivated Tel-SNV; C, Tel-Ampho with psoralen-inactivated, biotinylated Tel-Ampho. (d) Comparison of Tel-Ampho with Tel-SNV for use as light-activatable viral vectors. A, Tel-Ampho, biotinylated with 2.5 mg/ml NHS-PC-LC-biotin, stored in the dark; B, Tel-Ampho, biotinylated as A, and subsequently exposed to 365 nm light for 3 min; C, Tel-Ampho, treated with an equivalent amount of DMF as in A and B (with no biotinylation reagent), stored in the dark; D, Tel-SNV, biotinylated as A, stored in the dark; E, Tel-SNV, biotinylated as D, and subsequently exposed to 365 nm light for 3 min; F, Tel-SNV, treated with an equivalent amount of DMF as D and E (no biotinylation reagent), stored in the dark. Data shown are representative of two independent experiments.
ing through lipid bilayers. 17 Hence, it should biotinylate only the outer surface of (enveloped) retroviral particles.
Also supporting the role of the envelope glycoprotein in biotinylation-mediated inactivation of infectivity is the observation that Tel-SNV (which is otherwise identical to Tel-Ampho except that it bears the envelope glycoprotein of SNV instead of that of amphotropic MLV) showed a behavior very different from Tel-Ampho when treated with NHS-PC-LC-Biotin. While the infectivity of Tel-SNV was effectively inactivated by treatment with NHS-PC-LC-Biotin, exposure of the resulting biotinylated Tel-SNV Gene Therapy with 365 nm light did not restore viral infectivity (Figure 4d ). Because the only difference between the TelAmpho and Tel-SNV particles is the type of envelope glycoprotein displayed, it is implied that the phenomenon of light-facilitated infectivity activation involves the inactivation and subsequent reactivation of the function of the viral envelope glycoprotein.
Discussion
Here we have demonstrated the potential for the creation of viral vectors with externally activatable infectivity. Using a photocleavable reagent and simple procedures, the infectivity of an amphotropic retroviral vector species can be nearly or completely eliminated. Upon exposure of these viral vectors to light, infectivity was restored to these viral vectors. This strategy of activatable infectivity worked in either the presence or absence of viral target cells, demonstrating its ability to provide effective control over the transduction of genes by amphotropic viral vectors. Possible applications of viral vectors with activatable infectivity are numerous. For example, the infectivity of amphotropic vectors, normally not targetable due to the lack of tissue or cell-type specificity, could conceivably be activated within specific areas by a directed, focused application of light. Because treatment with NHS-PC-LC-Biotin results in the attachment biotin moieties to retroviral vectors, it may be possible to conjugate biotin-binding proteins, such as avidin and streptavidin to these biotinylated and inactivated vectors. Streptavidin could function as a bridge to conjugate a variety of targeting reagents, such as single-chain antibodies against cell-surface molecules of target cells, to the surface of biotinylated and inactivated viral vectors. Retroviral vectors with activatable infectivity may also be useful as a research tool, where either temporal or spatial control of an infection is desired. Additionally, the ability to switch infectivity off or on might be desirable for safe handling of highly contagious or dangerous pathogens. The transportation of such pathogens might also be made safer if their infectivity could be inactivated before transport, to be restored upon reception.
We are finding that a number of human cell lines behave similarly to the D-17 line (data not shown). However, the current treatment concentration (2.5 mg/ml) of NHS-PC-LC-Biotin resulted in varied levels of inactivation from cell line to cell line. This suggests that optimization of treatment conditions may be required for each cell type in question.
Materials and methods
Cell lines and virus production
The dog osteosarcoma cell line, D-17 (10) (American Type Culture Collection, Manassas, VA, USA) was maintained in Dulbecco's modified Eagle's medium (DMEM; Cellgro, Herndon, VA, USA) supplemented with 6% fetal bovine serum and penicillin-streptomycin. A human rhabdomysarcoma cell line, TelCeB6, 3 was maintained in DMEM supplemented with 10% FBS and penicillin-streptomycin.
For production of retroviral stocks bearing the amphotropic envelope from 4070A murine leukemia virus (TelAmpho), TelCeB6 cells (10 7 ) were cultured overnight in 150-mm culture dishes. These cells produce murine leukemia virus particles that possess gag and pol gene products, but lack envelope glycoprotein. Cells were transfected by the calcium-phosphate method with 20 g of the plasmid, pA, 3 which expresses the amphotropic envelope glycoprotein of 4070A murine leukemia virus. After transfection (72 h), culture media containing TelAmpho retroviral vectors were collected, and centrifuged at 4000 g for 10 min. Supernatants were then divided into aliquots and stored at −70°C. Production of retroviral vectors bearing the spleen necrosis virus (SNV) envelope glycoprotein was accomplished by the method described above, using a plasmid, pRD134, that efficiently expresses the envelope glycoprotein of SNV. 5 
Infectivity assays
To determine the infectivities of retroviral vectors, virus particles were placed over monolayers of D-17 cells (10 000 per well, in a 96-well plate, or 40 000 per well in a 24-well plate) in a total volume of 100 l or 200 l, respectively, of DMEM/10% FBS containing 5 g/ml polybrene. After exposure of retroviral vectors to D-17 cells (48 h), cells were fixed in 0.5% paraformaldehyde and stained for the expression of lacZ gene using 5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside (X-gal) as the substrate. Infected (lacZ-expressing) cells, which possessed easily identifiable blue nuclei, were counted under a light microscope. For analysis of the time-course of biotinylated virion infectivity versus irradiation with long-wavelength UV light, a Tel-Ampho stock solution (2 ml) was subject to ultrafiltration to a final volume of 200 l using filtration devices (YM-100, Millipore, Bedford, MA, USA) with a molecular mass cut-off of 100 kDa. This was followed by dilution of the concentrated viral vector with PBS (pH 7.4) to a volume of 2 ml. This process was repeated, and the resulting viral vector stock was concentrated to a volume of 200 l by ultrafiltration. Concentrated viral vectors were then treated with 2.5 mg/ml NHS-PC-LCBiotin for 150 min on ice. Treated viral stocks were placed in borosilicate glass vials and subject to irradiation with long wavelength (365 nm) UV light at a distance of 0.5 cm, utilizing a UVL-21 lamp (720 W/cm 2 at 15 cm distance) (UV Products, Upland, CA, USA). At the intervals shown, samples (10 l) of virus were removed from vials and subjected to infectivity assays, as described above.
Western blotting analysis
Tel-Ampho (3 ml) was filtered by passage through a 0.45-m filter. Filtered viral vector was centrifuged at 8000 g for 10 min at 4°C. The supernatants were concentrated to a volume of 200 l by YM-100 ultrafiltration (100 kDa molecular mass cut-off). Viral vectors were treated with 2.5 mg/ml NHS-PC-LC-Biotin/10% DMF for 150 min on ice in the dark. An equal volume of 100 mm glycine/PBS (pH 7.4) was added to the biotinylated viral vectors, and the mixture was placed on ice, in the dark for 30 min.
The treated viral vectors were subjected to ultrafiltration to reduce the volume to 200 l. This concentrated, biotinylated viral vector was placed in a 2.5-ml (7.5-cm length) Sephacryl S-1000 gel filtration chromatography column. Viral vectors were eluted with PBS (pH 7.4), and fractions from 400 l to 1500 l were collected (determined to be the virus-containing fractions). Purified viral vector (500 l) was stored in the dark at room temperature or exposed to irradiation by 365-nm light for 6 min at a distance of 0.5 cm (as described above). These viral vectors were centrifuged at 24 000 g at 4°C for 2 h to pellet the viral vector particles. Pelleted viral vectors were suspended in 15 l of an SDS-containing sample buffer and subjected to SDS-PAGE 12 using 10-20% polyacrylamide gradient gels. Proteins were blotted on PVDF membrane that was then blocked with SuperBlock (Pierce). Blots were incubated for 1 h in a 1/10 000 dilution of a streptavidin-peroxidase conjugate (Pierce) in SuperBlock containing 0.02% Tween 20. Binding of the streptavidinperoxidase conjugate was detected by using an enhanced chemiluminescence (ECL) kit (Amersham, Piscataway, NJ, USA). To detect all viral components on blots, TelAmpho (1 ml) were subjected to ultrafiltration using a YM-100 filtration unit to a final volume of 100 l. The concentrated viral vectors were subjected to albumin removal using an albumin serum removal kit (Genomic Solutions, Ann Arbor, MI, USA) following the protocol as described by the manufacturer. The resulting viral vector solution was centrifuged at 24 000 g for 2 h at 4°C. The viral pellet was dissolved in 15 l of an SDS-containing sample buffer, and 5 l of the resulting lysed virus was loaded into the same gel and blotted on to the same membrane as above. The blot was then blocked as described above and subsequently incubated with a 1/10 000 dilution of goat polyclonal antisera against disrupted Rauscher leukemia virus (ID 71S000126, NCI/BCB Repository), which crossreacts with the protein components of Moloney murine leukemia virus. Blots were then treated with a 1/100 000 dilution of sheep anti-goat polyclonal antibodies conjugated to peroxidase and subjected to ECL for visualization.
Reverse transcriptase assays
Tel-Ampho vector (6 ml) was pelleted by centrifugation at 24 000 g for 2 h at 4°C. The viral pellet was resuspended in 130 l of PBS (pH 7.4). Concentrated viral vector (80 l) was then treated with 2.5 mg/ml NHS-PC-LCBiotin/10% DMF for 150 min on ice, in the dark. In parallel, 40 l of the concentrated viral vector was with 10% DMF alone for 150 min on ice, in the dark. NHS-PC-LCBiotin-treated viral vector (40 l) was exposed to 365-nm light for 6 min at a distance of 0.5 cm as described above. The other 40 l of biotinylated vector was allowed to stand in the dark at room temperature for 6 min. All viral vectors were then divided into 20 l aliquots, each mixed with 20 l of a lysis buffer (50 mm Tris-Cl, 80 mm potassium chloride, 2.5 mm DTT, 0.75 mm EDTA, and 0.5% Triton X-100, pH 7.8). Lysed viral vectors were then combined with 50 l of a reverse transcriptase reaction buffer containing deoxyribonucleotides and template RNA (provided by the Non-Radioactive Reverse-Transcriptase Assay Kit, Boehringer Mannheim, Indianapolis, IN, USA). Manganese chloride was added to a final concentration of 12 mm. ␣-32 P-dTTP, 7 l, was also added to allow for detection of RT reaction products. Lysed viral Gene Therapy vectors mixed with the reaction buffer were incubated at 42°C and incubated overnight. Each reaction mixture (10 l) was spotted on DE81 filter paper (Whatman, Clifton, NJ, USA), dried, and washed three times with 2 × SSC. After washing, the spotted filter papers were dried after soaking them in 95% ethanol and radioactivity was assessed by liquid scintillation counting.
Viral interference assays
Inactivated Tel-Ampho particles were prepared by treating a stock of Tel-Ampho with a psoralen derivative, AMT, followed by irradiation with long-wavelength UV light. These psoralen-inactivated viral vectors were tested for their ability to interfere with the infection of viral target cells (D-17) by unaltered Tel-Ampho. In parallel, Tel-SNV (TelCeB6-derived viral cores bearing the envelope glycoprotein of spleen necrosis virus) and NHS-PC-LCBiotin-treated Tel-Ampho (using 2.5 mg/ml NHS-PC-LCBiotin) were also tested for their ability to interfere with the ability of unaltered Tel-Ampho vectors to infect target D-17 cells. Stocks of inactivated Tel-Ampho and Tel-SNV particles were constructed as follows. The viral vector stock (1.6 ml) was combined with 4′-aminomethyl-4,5′,8-trimethylpsoralen (AMT) at a final concentration of 50 g/ml. After 30 min of incubation at room temperature in the dark, viral vector-AMT mixtures were exposed to 365 nm for 15 min at a distance of 2 cm from the light source. Following irradiation, AMT-inactivated viral vector was centrifuged at 8000 g for 10 min at 4°C to remove gross cellular debris. Virus-containing supernatants were then concentrated to a volume of 420 l by ultrafiltration using YM-100 (100 kDa molecular mass cut-off) filtration devices. Concentrated viral vector was separated into two 200-l aliquots and treated with either 2.5 mg/ml NHS-PC-LC-Biotin/10% DMF or 10% DMF alone, on ice in the dark for 150 min, followed by addition of 200 l of 100 mm glycine/PBS (pH 7.4). Inactivated, concentrated and NHS-PC-LC-Biotin-treated (or non-biotinylated) viral vector (20 l) was then combined with 2.5 l of unaltered Tel-Ampho from the same viral vectors stock as the one used to prepare inactivated viral particles. These mixtures were placed over monolayers of either 1 × 10 4 or 5 × 10 3 D-17 cells in a total volume of 100 l of DMEM/6% FBS containing 5 g/ml polybrene. After 4 h of incubation at 37°C, the culture medium over the D-17 cells was replaced with fresh DMEM/6% FBS. After exposure of cells to viral vectors (48 h), cells were fixed in 0.5% paraformaldehyde and stained with X-gal to reveal infected (lacZ-expressing) cells as described above.
